Evidence map›Paper›PMID 35004336›Full record

ArticleFrontiers in oncology2021

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study.

Biao Yang, Luo Jie, Ting Yang, Mingyang Chen, Yuemei Gao, Tian Zhang, Yuzu Zhang, Hao Wu, Zhengyin Liao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Review
  10. Transarterial chemoembolization combined with lenvatinibWorld journal of gastrointestinal oncology · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Biao YangDepartment of Gastroenterology, West China Medical School, Sichuan University, Chengdu, China.
Luo JieDepartment of West China School of Public Health, Sichuan University, Chengdu, China.
Ting YangDepartment of Abdominal Oncology, West China Medical School, Sichuan University, Chengdu, China.
Mingyang ChenDepartment of Stomatology, Hospital of Stomatology, Sichuan University, Chengdu, China.
Yuemei GaoDepartment of Abdominal Oncology, West China Medical School, Sichuan University, Chengdu, China.
Tian ZhangWest China Medical School, Sichuan University, Chengdu, China.
Yuzu ZhangWest China Medical School, Sichuan University, Chengdu, China.
Hao WuDepartment of Gastroenterology, West China Medical School, Sichuan University, Chengdu, China.
Zhengyin LiaoDepartment of Abdominal Oncology, West China Medical School, Sichuan University, Chengdu, China.
West China Medical Center of Sichuan University · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis study aimed to compare the efficacy of transarterial chemoembolization (TACE) plus sorafenib (TACE-S) to TACE plus lenvatinib (TACE-L) for the treatment of HCC with portal vein tumor thrombus (PVTT).

methodsThis cohort study recruited patients from September 2017 to September 2020. A total of 59 and 57 consecutive patients were treated with TACE-L and TACE-S, respectively.

resultsBefore propensity score matching (PSM), comparing TACE-L to TACE-S, the median overall survival (OS) time was 16.4 months and 12.7 months, respectively [hazard ratio (HR) 1.34; 95% confidence interval (CI): 0.81-2.20;

conclusionBoth TACE-L and TACE-S are safe, well-tolerated treatments for HCC with PVTT. In HCC with PVTT, TACE-L was significantly superior to TACE-S with respect to OS, PFS, and ORR. A larger-scale randomized clinical trial is needed.

Indexed as

hepatocellular carcinomalenvatinibportal vein thrombosissorafenibtranscatheter arterial chemoembolization

Identifiers

PMID35004336
PMCPMC8733478
OpenAlexW4200229374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.